Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biota has released preliminary results from study of household iInfluenza prophylaxis effect of long-acting anti-influenza drug (SHIELD) Phase III prophylaxis study of laninamivir octanoate (CS-8958 or Inavir) in families of influenza A and B sufferers.
Subscribe to our email newsletter
Inavir is the first of a new class of long acting neuraminidase inhibitors (LANIs) designed to address the limitation of the current influenza anti-virals, which require daily or more frequent dosing
The Phase III double-blind, multicenter, placebo-controlled trial investigated the prevention and safety of laninamivir octanoate in families of influenza A and B sufferers.
The trial results showed the protective efficacies of a single, inhaled dose of CS-8958 of 20mg and 40mg were 43.7% and 43.2% respectively but were lower than the preset RRR endpoint of 70% as as measured by the Risk Reduction Rate (RRR).